Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Carcinogenesis

Co-Targeting KRASG12D and the HER family is efficacious in colorectal cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMary Kate Kilroy-GehretCWCecilia WischmeierBPBriley SoYoung Park

Discussion

Loading...

Member takes

Overview

This research shows reduced colorectal cancer growth when co-targeting KRAS and HER3, suggesting new treatment strategies.

Key Points

  • Co-targeting KRASG12D and HER3 significantly reduces colorectal cancer cell growth, indicating a potential treatment avenue.
  • Increased HER3 levels were observed in colorectal cancer samples treated with KRAS-targeted therapies, suggesting a resistance mechanism.
  • Genetic knock-down of both KRAS and HER3 was more effective in reducing cell viability than targeting either one alone.
  • Co-treatment with pan-HER inhibitors alongside KRASG12D inhibitors resulted in additive effects on reducing cell growth in colorectal cancer.

Cite This Study

Kilroy-Gehret et al. (2025) studied this question.

synapsesocial.com/papers/68c2404eb210217d64799bcchttps://doi.org/10.1093/carcin/bgaf036
View Full Paper
Ask AI
Bookmark
Share